Latham & Watkins Advises Precision BioSciences on US$125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Precision BioSciences, Inc. (Nasdaq: DTIL) (Precision), a clinical-stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, has announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of US$7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of US$7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the US$0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Precision from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately US$125 million. The deal includes participation from new and existing investors, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments, Driehaus Capital Management, as well as other leading life sciences investors.

Latham & Watkins LLP represents Precision in the offering with a corporate team led by partners Nathan Ajiashvili and Peter Handrinos, with associates Jie Lin Nai and Jessmine Lee.